Kornimate/medical-research-clean huggingface dataset:
device-detected paroxysmal atrial fibrillation

Conditions: Atrial Fibrillation

Summary: this study will use an automated blood pressure monitor (microlife watchbp03) with an inbuilt algorithm to detect atrial fibrillation (an irregular heart rhythm) in patients with an implanted pacemaker who have previously documented paroxysmal (intermittent) atrial fibrillation. this study will compare the microlife device detected atrial fibrillation episodes to the pacemaker detected atrial fibrillation episodes.

the modified microlife blood pressure monitor is able to detect atrial fibrillation (af) with high sensitivity (95%) and specificity (86%) and has a positive predictive value of 68% and negative predictive value of 98% for single readings. in addition, the modified device was also able to accurately classify the majority of the anomalous non-af rhythms, although the specificity was highly variable, dependent upon the rhythm. however sinus rhythm was detected with a specificity of 97%. however, we do not currently know if the device would demonstrate a similar sensitivity in detecting af in patients with paroxysmal af. therefore, the present study will assess the sensitivity and specificity of the automated oscillometric device using a new af algorithm among pacemaker patients with fast af and atrial high-rate episodes and evaluate the effect of the specific rhythm abnormalities on the specificity for af.

Eligibility criteria:
inclusion criteria: * patients with an implanted pacemaker for sick sinus syndrome with previously documented af with atrial high-rate episodes exclusion criteria: * any patient who's pacemaker has had previously documented atrial sensing or pacing problem issues * patients with permanent af

Keywords: atrial fibrillation; pacemaker; device-detected; sensitivity; specificity
coolsculpting treatment in the upper arms

Conditions: Body Fat Disorder

Summary: evaluate the safety and efficacy of the zeltiq coolsculpting system using specialized vacuum applicators for non-invasive subcutaneous fat reduction of the upper arms.

subcutaneous fat reduction of the upper arms using 2 vacuum applicator types will be done concurrently, such that a subject will have an applicator placed on each arm simultaneously.

Eligibility criteria:
inclusion criteria * male or female subjects \> 22 years of age and \< 65 years of age. * subject has clearly visible fat sufficient for treatment on the upper arm, which in the investigator's opinion, may benefit from the treatment. * no weight change exceeding 5% in the preceding month. * subject agrees to maintain his/her weight (i.e., within 5% of total body weight) by not making any major changes in their diet or exercise routine during the course of the study. * subject has read and signed the study written informed consent form. exclusion criteria * history of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.), or implants in or adjacent to the area of intended treatment. * history of prior surgery in the arms. * known history of cryoglobulinemia, cold urticaria, cold agglutinin disease, or paroxysmal cold hemoglobinuria. * known history of raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. * history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. * history of carpal tunnel syndrome, compartment syndrome or deep vein thrombosis in the upper extremities. * currently taking or has taken diet pills or weight control supplements within the past month. * any dermatological conditions, such as scars, infection, in the location of the treatment area that may interfere with the treatment or evaluation. * active implanted device such as a pacemaker, defibrillator, or drug delivery system. * pregnant or intending to become pregnant in the next 5 months. * lactating or has been lactating in the past 6 months. * unable or unwilling to comply with the study requirements. * currently enrolled in a clinical study of any other unapproved investigational drug or device. any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
a prospective evaluation of clinical equivalence between ix and pid

Conditions: Wound

Summary: patients with chronic wounds will be imaged using 2 imaging devices. two types of images will be acquired with each device, a standard photograph (st-image) and a fluorescence image (fl-image). the images captured with the 2 imaging devices will be compared off-line by many interpreters to assess for any differences in the images that would alter a clinical decision.

patients (n = 50) with chronic wounds will be imaged using 2 imaging devices. two types of images will be acquired with each device, as standard photograph (st-image) and a fluorescence image (fl-image). the images captured with the 2 imaging devices will be compared off-line by many interpreters to assess for any differences in the images that would alter a clinical decision.

Eligibility criteria:
inclusion criteria: 1. male and female subjects presenting at an advanced outpatient wound care clinic with wound(s) of unknown infection status 2. 18 years of age or older exclusion criteria: 1. treatment with an investigational drug within 1 month before study enrollment 2. subjects with recent (\<30 days) biopsy or curettage of target wound 3. subjects with wounds that cannot be completely imaged by study device due to anatomic location 4. unable or unwilling to consent

Keywords: wound imaging
japanese single and multiple ascending dose, safety, tolerability, pharmacokinetic (pk) & pharmacodynamic (pd) study of azd7687

Conditions: Type 2 Diabetes; Obesity

Summary: this is a study in japanese healthy volunteers to determine the safety and tolerability of the compound azd7687. it will also assess how the body handles the drug and how it responds to the drug following single dose followed by multiple dosing over 7 days.


Eligibility criteria:
inclusion criteria: * suitable veins for cannulation or repeated venipuncture * have a body mass index (bmi) between 19 and 35 kg/m2 and weigh at least 50 kg and no more than 90 kg * male subjects should be willing to use barrier contraception ie, condoms with spermicide, from the first day of dosing until 3 months after the last dose of investigational product exclusion criteria: * history of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study. * history or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs * any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product

Keywords: phase 1 type 2 diabetes obesity japanese healthy volunteer azd7687
feasibility of deep inspiratory internal jugular vein variability in guiding preoperative fluid replacement

Conditions: Hemodynamic

Summary: compare the incidence of hypotension during the propofol-induced period between the internal jugular vein variability-guided fluid infusion group and the conventional fluid infusion group through a fluid infusion experiment before anesthesia induction, so as to evaluate the feasibility of using the internal jugular vein variability under deep inspiration to guide preoperative fluid infusion.

ultrasound records at least one quiet breathing cycle and one deep inhalation cycle to calculate ijvv propofol was infused target-controlled at 4 μg/ml, and changes in arterial blood pressure within 3 minutes of propofol induction were observed. plan to conduct a prospective randomized controlled study to compare the incidence of hypotension during the propofol-induced period between the internal jugular vein variability-guided fluid infusion group and the conventional fluid infusion group through a fluid infusion experiment before anesthesia induction.

Eligibility criteria:
inclusion criteria: * age over 60 years； american society of anesthesiology (asa) status ⅱ-ⅲ； surgery with radial artery puncture； propofol induction； exclusion criteria: * bmi≥30kg/m2； people with short necks； previous hypotension (systolic blood pressure \<90mmhg or mean arterial pressure\<65mmhg)； previous poorly controlled hypertension； cardiac insufficiency , ef value\<50%； upper limb deep vein thrombosis； history of radiotherapy or neck surgery； inability to maintain a supine position for necessary measurements； mechanical ventilation status or inability to take deep breaths patients； gastrointestinal surgery； patients allergic to propofol； restricted fluid intake；

Keywords: internal jugular vein propofol hemodynamic hypotension fluid replacement
description of drug utilization and assessment of impact of saxagliptin on health status of patients with type 2 diabetes in france

Conditions: Type 2 Diabetes Mellitus (T2D)

Summary: the purpose of this study is to respond to the french health authority which has requested bms france and astra zeneca (az) france to set-up a long-term cohort study in a representative sample of french type 2 diabetes mellitus (t2d) patients treated with saxagliptin to generate real world data on drug utilization, joint population, non comparative effectiveness and safety

time perspective: ambispective cohort follow by a 18 to 24 month follow up period, retrospective follow by prospective.

Eligibility criteria:
inclusion criteria: * registry * patient ≥ 18 years old * patient with t2d * ambispective cohort * patient ≥ 18 years old * patient with t2d * patient initiated with saxagliptin in the last 6 months before the inclusion or day of inclusion visit (whatever his/her ongoing hypoglycaemic treatment) * patient agreeing to participate, and not yet enrolled by another physician exclusion criteria: * patient participating in a clinical trial
comparing two surgical methods of fixation of subscapularis during shoulder arthroplasty

Conditions: Subscapularis Peel; Morselized Osteotomy

Summary: this pilot study is being conducted to compare 2 methods of access to the shoulder for arthroplasty in patients with osteoarthritis as we do not know has a better outcome.

the study investigates the difference in disease specific quality of life between patients who undergo a subscapularis peel versus morselized osteotomy of the lesser tuberosity, as measured by the western ontario osteoarthritis of the shoulder (woos) at one year post-operatively in patients who undergo shoulder arthroplasty ?

Eligibility criteria:
inclusion criteria: * patients who have failed standard non-surgical management of their shoulder arthritis who would benefit from a shoulder arthroplasty. exclusion criteria: * active joint or systemic infection * significant muscle paralysis * rotator cuff tear arthroplasty * major medical illness * unable to speak or read english/french * psychiatric illness that precludes informed consent * unwilling to be followed for 1 year

Keywords: osteoarthritis shoulder subscapularis peel osteotomy
bleeding in hospitalized patients with liver disease undergoing invasive procedures

Conditions: Bleeding; Procedural Complication; Cirrhosis, Liver; Coagulation Disorder, Blood

Summary: patients with cirrhosis are frequently hospitalized and often undergo procedures. knowledge surrounding bleeding risk is sparse and practice patterns vary across centers in regards to bleeding prophylaxis. the goal of this study to is to obtain more knowledge regarding risk factors for procedural related bleeding in patients with cirrhosis and to develop a predictive model to risk stratify patients before undergoing procedures. through collaboration from centers across the world this study should provide information on prevalence of bleeding and variation in practice patterns for prophylaxis.

hospitalized patients with cirrhosis who undergo 1 or more non-surgical procedure will be enrolled. the investigators will collect multiple clinical characteristics from the medical record and follow the patients prospectively over the hospitalization and/or until 28 days to determine if clinical events have occurred including bleeding, thrombosis, re-hospitalization and death. characteristics of the hospitalization will be recorded including presence of acute decompensation and acute on chronic liver failure (aclf). procedure type will be recorded including coagulation laboratory data before and after each procedure. all bleeding events will be recorded and characteristics surrounding each bleed will be recorded. bleeding will be defined according to international thrombosis and haemostasis (isth) definitions of major bleed and clinically relevant non-major bleed. redcap (https://www.project-redcap.org) will be used to collect and centralize data maintained at the university of virginia. characteristics of each hospitalization will be recorded accordingly and patients will be followed for 28 days for outcome and mortality information. each participating center will obtain local institutional review board (irb) approval to participate and enter data directly into redcap. after center irb approval is obtained, centers will consecutively enrolling patients on a rolling basis. data will be collected from enrollment until death, transplant, discharge and/or 28 days on each individual enrolled.

Eligibility criteria:
inclusion criteria: * adult patients with cirrhosis admitted to a hospital ward or icu for greater than 24 hours. * patient must undergo 1 or more invasive non-surgical procedures at admission or during the hospitalization. exclusion criteria: * age \< 18 years old * prisoner * pregnant * unable to provide consent * previously enrolled in this study

Keywords: decompensated liver coagulopathy aclf
sense of hope alleviates fatigue in breast cancer survivors

Conditions: Carcinoma of Male Breast

Summary: this study explores the relationship between the sense of hope and fatigue in breast cancer survivors and provides a reference for future planning improvements for breast cancer survivors experiencing fatigue.

breast cancer is an important and escalating issue for females all over the world. due to the improvement of medical and technological progress, the survival rate of breast cancer patient increases every year. breast cancer survivors, after the discomforting distress from cancer treatment, will go through treatment-derived physical distress and worry about relapse. as a result the fatigue in breast cancer survivors has not been reduced after primary treatment. feeling fatigue in a long term will bring mental illness problems ,decrease the quality of life and weaken the will to survive. a sense of hope in the face of fatigue may serve as an important driving force and enhance the survivors' will to survive. this study explores the relationship between the sense of hope and fatigue in breast cancer survivors and provides a reference for future planning improvements for breast cancer survivors experiencing fatigue. a cross-sectional study design is adopted for this study. the study expects to collect 200 questionnaires from breast cancer survivors through medical centers treating breast cancer and breast cancer patients communities. the questionnaire includes (a) the basic demographic information (b) disease history (c) social support scale; (d) short version multiaxial fatigue syndrome scale; (e) hearst hope scale. answered questionnaires will be input to spreadsheets for further statistical analysis using spss 19.0 statistical software packages.

Eligibility criteria:
inclusion criteria: 1. diagnosed as a breast cancer patient 2. complete operation,chemotherapy and radiation therapy 3. understand the treatment and condition by herself 4. conscious clear who can speaking mandarin or: taiwanese 5. after consenting , the participant agree to participate orally or write down in the consent form exclusion criteria: 1. can not speaking mandarin or taiwanese 2. psychotic or understanding barriers 3. refuse verbally or write the consent form

Keywords: breast cancer
assessing the efficacy of targeted home visits in the management of chronic conditions

Conditions: Hypertension; Type 2 Diabetes

Summary: the purpose of study is to evaluate whether home visit programs are an effective method for htn and t2dm management as compared to standard of care clinic visits.

the purpose of this study is to compare the health outcomes utilizing home medical visits to manage hypertension and type 2 diabetes as compared to standard of care clinic visits. this project has 3 overall objectives: 1. to test the efficacy of home medical visits by family medicine physicians specifically designed for patients with hypertension (htn) and type 2 diabetes mellitus (t2dm) 2. to compare primary outcome of the patients randomly selected for home visits to similar patients receiving usual care in the clinical setting 3. to understand the efficacy and impact of the home visit from the patient perspective study participant will receive usual care from a resident doctor in home. there will be (2) home visits conducted over the course of this study that will include a comprehensive assessment of hypertension, type 2 diabetes, and social factors that may be impacting their health. study participants will also be asked to complete several questionnaires related to their knowledge of chronic diseases, personal health management, and experience of the study home visits.

Eligibility criteria:
inclusion criteria: * adult patients ages 18-60 * spanish or english speaking * diagnosis of htn or bp \>140/90 in last 3 months (based on medical record) * hemoglobin a1c\>8 in last 6 months (based on medical record) * not pregnant exclusion criteria: * current oral steroid use * history of solid organ transplant * language other than english or spanish
identification of ventricular fibrillation and optimization of defibrillation during cpr

Conditions: Cardiac Arrest; Identify of Electrocadiac Rhythm

Summary: it's so important to recognize ventricular fibrillation in cardiac arrest and defibrillation early. at the same time research findings have identified high-quality cpr with minimum interruption is critical to the success of defibrillation therapy. both the guidelines by american heart association and the guidelines by european resuscitation council emphasize the importance of minimizing interruptions in chest compressions, specifically, duration of the pre-shock and post-shock pauses. so aha indicate that there will be a new algorithm of vf during chest compression, which has high sensitivity and specificity. and the investigators can identify vf and defibrillate earlier. the aim of this study is to verify that if sherlock algorithm of philips mrx monitor/defibrillator can identify shockable rhythms during chest compression accurately.


Eligibility criteria:
inclusion criteria: 1. cardiac arrest patients 2. the length from cardia arrest to be rescued is less than 10 minutes 3. age≥14 4. complied with ethical requirements 5. signing the informed consent form. exclusion criteria: 1. dnr 2. pregnant women

Keywords: cardiac arrest identify of electrocardiac rhythm ventricuar fibrillation defibrillation
pentosan polysulfate sodium and meclofenamic acid as treatments in patients with psychotic disorders

Conditions: Psychotic Disorders; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder

Summary: this study evaluates the feasibility of administering meclofenamic acid or pentosan polysulfate sodium as an adjunctive treatment to patients diagnosed with a psychotic disorder. half of participants will receive meclofenamic acid, while the other half will receive polysulfate sodium.

chronic, low-grade brain inflammation is involved in the development of schizophrenia and other psychotic disorders. medications with anti-inflammatory properties, like meclofenamic acid and pentosan polysulfate may help to reduce brain inflammation and serve as a treatment of psychotic disorders.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar i disorder, delusional disorder, other specified schizophrenia spectrum and other psychotic disorders, unspecified schizophrenia spectrum and other psychotic disorders * negative pregnancy test in females of childbearing age exclusion criteria: * urine drug screen positive for psychostimulants such as cocaine, amphetamines and ecstasy * any infection, neoplasm, autoimmune disease or other primary inflammatory condition (3) previous diagnosis of intellectual disability or dementia * current treatment with heparin * use of or allergy to non-steroidal anti-inflammatory agent or pentosan polysulfate sodium * current or anticipated corticosteroid use * history of peptic ulcer disease, gastro esophageal reflux disease, or gastrointestinal bleeding * those on warfarin or any anticoagulant * current treatment with lithium or asthma medication * individuals with pre-existing liver, cardiac, or kidney disease

Keywords: psychotic schizophrenia schizoaffective bipolar